Veradigm - MDRX STOCK NEWS

Veradigm, a healthcare data and technology solutions provider and a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has announced a new agreement with Vytalize Health, a Medicare ACO. This collaboration will see Vytalize Health's solutions integrated into the Practice Fusion EHR, enhancing value-based care for primary care physicians. The aim is to improve patient outcomes and reduce healthcare costs through personalized care plans and clinical support. This partnership positions Veradigm at the forefront of the shift toward value-based care in the U.S.

Veradigm, a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has been ranked #1 in Black Book's 2022 survey for Ambulatory Claims Management and Clearinghouse Solutions. Veradigm Payerpath is recognized for its robust revenue cycle management capabilities, achieving a first-pass clean claims rate exceeding 98% and interfacing with over 3,100 payers. This award highlights Veradigm's commitment to improving healthcare connections and enhancing practice profitability. The Black Book ranking emphasizes operational excellence across 18 performance areas, based on user feedback.

Allscripts Healthcare Solutions (MDRX) reported a 10% increase in year-to-date bookings, totaling $172 million. The second quarter of 2022 saw revenues of $151 million, up from $141 million in 2021. Veradigm's revenue rose to $145 million, a gain from $133 million YoY. Despite a GAAP loss from operations of $5 million, adjusted EBITDA improved to $39 million. The company affirms its financial outlook for 2022, projecting 6-7% revenue growth and free cash flow between $110-120 million. Stock repurchases amounted to $94 million in Q2.

Allscripts Healthcare Solutions (NASDAQ: MDRX) is set to report its financial results for Q2 2022 on August 4, 2022, after market close. The announcement will include details on the earnings call scheduled for 4:30 PM ET the same day. The earnings announcement will be available on Allscripts' investor relations website. Investors can join the call via phone or through the website. A replay will be accessible for six months post-call.

Pulse8 has announced that its Qualit8 solution achieved MY2022 Measure Certification from the National Committee for Quality Assurance (NCQA) for the third consecutive year. This certification highlights the solution’s commitment to enhancing administrative efficiency and delivering value to health plan customers. The NCQA-Certified HEDIS Measurement Program offers various certifications, including Health Plan Measures and Hybrid Sampling. Veradigm's dedication to transparent analytics aims to reduce healthcare spending and waste while improving efficiency for its clients.

Veradigm, a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has received a patent for its innovative "Dynamic Intervention Planning" method. This system enhances risk adjustment programs by enabling clients to identify, assess, and prioritize opportunities effectively. According to Tom Langan, the company aims to reduce waste and improve accuracy in revenue predictions, thereby allowing better management of client programs. Veradigm uniquely positions itself in the market by controlling significant aspects of risk adjustment, which can lead to greater financial returns for health plans.

Allscripts (MDRX) announced that researchers from Veradigm will present health economics and outcomes research data on Covid-19, diabetes, NASH, and cardiovascular disease at ISPOR 2022 in Washington, D.C., from May 15-18, 2022. Key presentations will focus on real-world data to improve public health initiatives, including the Covid-19 Dashboard to guide outreach to underserved communities. Veradigm aims to harness diverse data sources for better clinical outcomes and decision-making. This research could enhance understanding of disease risk factors and public health response.

On May 5, 2022, Allscripts Healthcare Solutions (MDRX) announced its Q1 2022 financial results, revealing a GAAP diluted EPS of $0.17 and a non-GAAP diluted EPS of $0.13. The company generated $35 million in cash flow from continuing operations and reported Veradigm revenue of $136 million, up from $126 million in Q1 2021. Consolidated GAAP net income reached $23 million, a significant increase from $9 million last year. The company confirmed its annual outlook, expecting Veradigm revenue growth of 6% to 7% and adjusted EBITDA growth of 10% to 15%.